Genetic profile company ActX raises $6M, filing shows

ActX, a biotech company based in Seattle, has raised $6 million in equity funding and is seeking an additional $107,000 to further its work in genetic profile testing.

The company, founded in 2013, uses genetic testing to aid medical professionals screening patients for conditions based on hereditary risks. The technology empowers physicians to make decisions based on a patient’s genetic profile and helps patients understand how genetic conditions affect their children.

ActX is the latest Seattle biotech to raise funding in 2022. Other Seattle-based companies, such as Bonum Therapeutics, raised $93 million in a Series A, along with Cajal Neuroscience raising $96 million in a Series A round in November 2022.

READ THE STORY at Puget Sound Business Journal »